28 min

Managing Nonalcoholic Fatty Liver Disease Medication Talk

    • Medicine

TRC Editor, Dr. Lori Dickerson, PharmD, FCCP talks with Kenneth Cusi, MD, FACP, FACE,  Professor of Medicine and Chief of the Division of Endocrinology, Diabetes and Metabolism from The University of Florida about managing nonalcoholic fatty liver disease.
Listen in as they discuss considerations with managing nonalcoholic fatty liver disease (NAFLD)...including risk factors, screening, and treatment options.
You’ll also hear practical advice from panelists on TRC’s Editorial Advisory Board:
Anthony A. Donato, Jr., MD, MHPE, Associate Program Director, Internal Medicine from the Reading Health System, and Professor of Medicine at the Sidney Kimmel Medical College at Thomas Jefferson UniversityDouglas S. Paauw, MD, MACP, Professor of Medicine at the University of Washington School of MedicineCraig D. Williams, PharmD, FNLA, BCPS, Clinical Professor, Department of Pharmacy Practice at the Oregon Health and Science UniversityFor the purposes of disclosure, Dr. Cusi reports relevant financial relationships with Echosens, Inventiva, Nordic Pharma, Novo Nordisk, Poxel, Zydus (grants/research support); Ionis, Janssen, Genentech, Gilead, Madrigal, Merck, Novo Nordisk, Pfizer, Poxel, Terns Pharmaceuticals (consultant). The other speakers have nothing to disclose. All relevant financial relationships have been mitigated.
Pharmacist’s Letter offers CE credit for this podcast. Log in to your Pharmacist’s Letter account and look for the title of this podcast in the list of available CE courses.
If you’re not yet a Pharmacist’s Letter subscriber, find out more about our product offerings at trchealthcare.com. 
Follow or subscribe, rate, and review this show in your favorite podcast app. You can also reach out to provide feedback or make suggestions by emailing us at ContactUs@trchealthcare.com. 

TRC Editor, Dr. Lori Dickerson, PharmD, FCCP talks with Kenneth Cusi, MD, FACP, FACE,  Professor of Medicine and Chief of the Division of Endocrinology, Diabetes and Metabolism from The University of Florida about managing nonalcoholic fatty liver disease.
Listen in as they discuss considerations with managing nonalcoholic fatty liver disease (NAFLD)...including risk factors, screening, and treatment options.
You’ll also hear practical advice from panelists on TRC’s Editorial Advisory Board:
Anthony A. Donato, Jr., MD, MHPE, Associate Program Director, Internal Medicine from the Reading Health System, and Professor of Medicine at the Sidney Kimmel Medical College at Thomas Jefferson UniversityDouglas S. Paauw, MD, MACP, Professor of Medicine at the University of Washington School of MedicineCraig D. Williams, PharmD, FNLA, BCPS, Clinical Professor, Department of Pharmacy Practice at the Oregon Health and Science UniversityFor the purposes of disclosure, Dr. Cusi reports relevant financial relationships with Echosens, Inventiva, Nordic Pharma, Novo Nordisk, Poxel, Zydus (grants/research support); Ionis, Janssen, Genentech, Gilead, Madrigal, Merck, Novo Nordisk, Pfizer, Poxel, Terns Pharmaceuticals (consultant). The other speakers have nothing to disclose. All relevant financial relationships have been mitigated.
Pharmacist’s Letter offers CE credit for this podcast. Log in to your Pharmacist’s Letter account and look for the title of this podcast in the list of available CE courses.
If you’re not yet a Pharmacist’s Letter subscriber, find out more about our product offerings at trchealthcare.com. 
Follow or subscribe, rate, and review this show in your favorite podcast app. You can also reach out to provide feedback or make suggestions by emailing us at ContactUs@trchealthcare.com. 

28 min